Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Shun Lü(Shanghai Chest Hospital), Lin Wu(Central South University), Hong Jian(Shanghai Chest Hospital), Ying Cheng(Jilin Province Tumor Hospital), Qiming Wang(Henan Cancer Hospital), Jian Fang(Peking University), Ziping Wang(Peking University), Yanping Hu(Hubei Cancer Hospital), Liang Han(Xuzhou Central Hospital), Meili Sun(Jinan Central Hospital), Liyun Miao(Nanjing Drum Tower Hospital), Cuimin Ding(Fourth Hospital of Hebei Medical University), Jiuwei Cui(Jilin University), Ke Wang(Sichuan University), Baolan Li(Capital Medical University), Xingya Li(First Affiliated Hospital of Zhengzhou University), Feng Ye(First Affiliated Hospital of Xiamen University), Anwen Liu(Second Affiliated Hospital of Nanchang University), Yueyin Pan(Anhui Provincial Hospital), Shundong Cang(Henan Provincial People's Hospital), Hui Zhou, Xing Sun, Yuping Shen, Shuyan Wang, Wen Zhang, Yue He
Cited by 197
Abstract
Related Papers
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson , Barry S. Taylor, Levi Garraway et al.|Nature|2014|5.8k
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al.|New England Journal of Medicine|2017|5.2k
Multiple Imputation for Nonresponse in Surveys.
Peter Lynn, Donald B. Rubin|Journal of the Royal Statistical Society Series D (The Statistician)|1988|2.3k